I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On OCTOBER 6, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: Kimberly Rosa

OIPE
OCT 11 2005
PATENT & TRADEMARK OFFICE

PATENT
Attorney Docket No.: 02307E-127510US
Client Reference No.: 2001-1042

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Daniele Piomelli et al.

Application No.: 10/681,858

Filed: October 7, 2003

For: MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS

Examiner: Bernard Dentz

Art Unit: 1614

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the foreign patent and of the non-patent references [in compliance with the requirements of 1287 OG 163] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the International Search Report for the corresponding PCT application, PCT/US03/31844.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
FJM:mrv
60599184 v1

OIPE
OCT 11 2005
PATENT & TRADEMARK OFFICE
IAP2

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

	Complete if Known
Application Number	10/681,858
Filing Date	October 7, 2003
First Named Inventor	Piomelli, Daniele
Art Unit	1614
Examiner Name	Bernard Dentz
Attorney Docket Number	02307E-127510US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-3,275,512	09-27-1966	Lemin et al.	
	2	US-3,632,631	01-4-1972	Wright et al.	
	3	US-3,880,908	04-29-1975	Fields et al.	
	4	US-5,112,859	05-12-1992	Commons et al.	
	5	US-5,476,944	12-19-1995	Partis et al.	
	6	US-6,919,358	04-10-2003	Cheng et al.	
	7	US-6,908,939	07-17-2003	Bernardon, et al.	
	8	US-6,927,228	02-26-2004	Bernardon, et al.	
	9	US-2005/0137238	06-23-2005	Bernardon, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]	Number[4]	Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	10	WO	02/08185	A1	01-31-2002	F-Hoffmann-La Roche AG		☐
	11	WO	02/12210	A1	02-14-2002	Galderma Research & Development		☐
	12	WO	03/051841	A2	06-26-2003	Novo Nordisk A/S		Abst.
	13	WO	03/051842	A2	06-26-2003	Novo Nordisk A/S		☐
	14	EP	1 231 212	A1	08-14-2002	Pfizer Products Inc.		
	15	JP	8-92167	A	04-09-1996	Idemitsu Kosan Co.		☐
								Abst.
								☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] **Applicant's** unique citation designation number **(optional)**. [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/681,858
				Filing Date	October 7, 2003
				First Named Inventor	Piomelli, Daniele
				Art Unit	1614
(use as many sheets as necessary)				*Examiner Name*	Bernard Dentz
Sheet	2	of	2	*Attorney Docket Number*	02307E-127510US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	16	BARNES, J.H. et al., "The preparation and pharmacology of some phenolic carbamates and allophanates." J. Pharmacy Pharmacol., Vol. 13, pp. 39-48, (1961)	
	17	BISOGNO, T. et al., "Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications." Curr. Pharmaceut. Des., Vol. 8, 533-47 (2002)	
	18	BROWN, L.W. and A.A. Forist, "In vitro and in vivo hydrolysis of salicylanilide N-methylcarbamate and 4-biphenylyl N-methylcarbamate." J. Pharm. Sci., Vol. 61, No., 6, pp. 858-60 (1972)	
	19	KOHN, G.K., et al., "Some structural relations of a group of simple alkylphenyl N-methylcarbamates to anticholinestrase activity." J. Agric. Food Chem., Vol. 13, No. 3, pp. 232-5 (1965)	
	20	LOPEZ-RODRIGUEZ, M.L. et al., "Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects of fatty acid amidohydrolase." J. Med. Chem., Vol. 46, No. 8, pp. 1512-22 (2003)	
	21	QUESNELLE, C.A. et al., "Directed ortho metalation - cross coupling connections. Nickel (0)-catalyzed cross coupling of aryl triflates with organozinc reagents." Synlett, Vol. 5, No. 5, pp. 349-50 (May 1994)	
	22	SMITH, A., "FAAH better anxiolytics?" Nature Reviews Drug Discovery Vol. 2, p. 92 (2003)	
	23	WOODS, G.F. et al., "M-diarylbenzenes." J. Am. Chem. Soc., Vol. 73, pp 3854-6 (1951)	
	24	WOODS, G.F., "Preparation and properties of some polyphenyls." WADC Technical Report, 59-496, pp. 1-170 (1959)	

60599184 v1

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.